Winterlight Labs

Speech shows promise for multiple use cases in clinical trials, from novel endpoints to new QA tools for novel endpoints, and collaboration will drive these technologies forward. Speak to us today to see how speech biomarkers can support your study.

Liam Kaufman recently spoke to pharmexec.com’s Mike Hollan about the ways digital biomarkers are improving Alzheimer’s research by overcoming some of the unique challenges faced in this area of drug development. Check out the interview here: https://lnkd.in/eHAyc93E   #alzheimersdisease #digitalbiomarkers #clinicaltrials

Join us at #ISCTM today, where our team will unveil three new posters.   Rachel Newsome, PhD will present new data on using speech biomarkers to support the automated detection of CDR administration issues.   And Brónagh McCoy highlights new findings on remote verbal learning over repeated exposures, along with insights into deriving cross-cognitive task outcome measures using dimensionality reduction techniques.   You can catch their presentations today from 5:45-7:30pm.   #clinicaltrials #alzheimersdisease

This week, our team will head to Washington, DC, for the annual #ISCTM scientific meeting. Join us as we present our latest posters 22-23 February, 5:45-7:30pm.   Poster 1 - Towards fully automated rating scale review: Identifying a speech feature signature for administration variances in CDR interviews during Alzheimer’s Disease clinical trials. Rachel Newsome, PhD   Poster 2 - Remote verbal learning over repeated exposures for six months. Brónagh McCoy   Poster 3 – Deriving cross-cognitive task outcome measures using dimensionality reduction techniques. Brónagh McCoy   Get in touch with the team on the ground to find out more - Nicola Johnson, Bill Simpson

🌟 Join us on Feb 26th, 2024 for the "Machine Learning for Cognitive and Mental Health Workshop" https://lnkd.in/ercWKaW3 - a cutting-edge event that dives deep into leveraging multimodal machine learning to tackle challenges in mental health and cognitive disorders. 🔗 Register now for either in-person or online attendance through the AAAI conference website https://lnkd.in/ecZxWshU. Don't miss out on the chance to engage with keynote speakers, panel discussions, and breakthrough research. #ML4CMH #MentalHealthTech #CognitiveHealth #MachineLearning #AAAI2024

Discover the transformative impact of an automated quality assurance strategy in #neurology trials. Dive into insights from Celia Fidalgo, PhD and John Harrison as they explore this approach in their latest Clinical Leader article: https://lnkd.in/eSeeCiYW   #AQUA #clinicaltrials #research

How much speech data is needed to track language change effectively in Alzheimer’s disease (AD)? Our latest paper delves into the significance of audio duration in capturing language alterations among AD patients. 📈 We gathered 110 natural speech samples from decades of YouTube videos featuring 17 public figures. Among these, nine have developed AD. 456 language features were extracted from these snippets, with text-length sensitivity, comparability, and the ability to capture change over time analyzed across various sample lengths. 🗣 Understanding the pivotal role of sample length can support standardized language-based analysis of cognitive decline. This insight will help to make assessments more transferrable and enhance their efficiency in clinical trials. Read more about the impact of audio duration in detecting language changes.   #alzheimersdisease #research #digitalbiomarkers

The submission deadline for Machine Learning for Cognitive and Mental Health Workshop at Association for the Advancement of Artificial Intelligence (AAAI) 2024 has been extended to December 1st AOE. Don't miss out on this opportunity to submit your work and be part of the conversation! Find out more: https://lnkd.in/ePvzD_sJ #machinelearning #mentalhealth #neuroscience #cognitive #aging #depression #Alzheimers #AAAI2024 

Elevating #CNS and #neurology trials with Automated Quality Assurance (AQUA)   Clinical assessments in CNS and neurology are pivotal for tracking conditions and assessing treatment efficacy. Yet, challenges like obtaining specialized expertise, manual evaluations, and scaling can impede efficient progress and the likelihood of a trial's successful outcome. The solution? Automated Quality Assurance (AQUA) powered by speech analysis.  🚀 AQUA in action 🚀   Automation excellence: Manual quality control consumes significant time and resources, impeding prompt error resolution in administration and scoring. AQUA analyzes CNS scale administration audio, swiftly detecting deviations for corrective action.    Seamless scalability: Manual assessments are costly and struggle with scalability, frequently resulting in overlooked evaluations. AQUA seamlessly integrates and scales, guaranteeing comprehensive assessment reviews regardless of trial size.    Streamlined review process: Precision in clinical assessments demands specialized expertise. Automation streamlines dataset review, providing a cost-effective solution that boosts trial efficiency.   Higher quality data: Flawed delivery and errors in administration risk subpar data. AQUA ensures objectivity and consistency, setting the gold standard for complex CNS trial scales.   You can find out more about how AQUA is shaping the future of CNS and neurology trials in Celia Fidalgo, PhD and John Harrison’s recent contribution to Clinical Leader: https://lnkd.in/eSeeCiYW   #AQUA #research #clinicaltrials

Our new poster highlights our significant strides in validating digital speech assessments. This research emphasizes the efficiency and minimal burden of these patient-relevant measures, which are sensitive to disease progression in #alzheimers.   #digitalhealth #clinicaltrials #research